Vistagen Therapeutics Inc (VTGN)

07:23 AM

What analysts say about Vistagen Therapeutics Inc. stockExceptional earning trajectories - Autocar Professional

07:23 AM

05:56 AM

Is Vistagen Therapeutics Inc. a good long term investmentTremendous financial leverage - jammulinksnews.com

05:56 AM

03:31 AM

What drives Vistagen Therapeutics Inc. stock priceHigh-velocity capital appreciation - jammulinksnews.com

03:31 AM

Jul 22, 2025

Vistagen Therapeutics Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What makes Vistagen Therapeutics Inc. stock price move sharply2x Return Forecast - Newser

Jul 22, 2025

Jul 19, 2025

VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50-Day Moving AverageHere's Why - MarketBeat

Jul 19, 2025

Jul 18, 2025

Is Vistagen Therapeutics Inc. stock a good hedge against inflationHigh Confidence Trade Setups - beatles.ru

Jul 18, 2025

Jul 15, 2025

How Vistagen Therapeutics Inc. stock performs during market volatilityEntry Level Low Risk Picks - Newser

Jul 15, 2025

Jul 15, 2025

Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - Newser

Jul 15, 2025

Jul 15, 2025

Biotech Leader Vistagen Achieves Rare Double Honor: Mental Health Excellence and Workplace Culture Awards - Stock Titan

Jul 15, 2025

Jul 13, 2025

Mental Disorder Treatment Market CAGR 28.16% key trends with - openPR.com

Jul 13, 2025

Jul 11, 2025

Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay - MSN

Jul 11, 2025

Jun 26, 2025

15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey

Jun 26, 2025

Jun 25, 2025

Vistagen appoints Elissa Cote as Chief Corporate Development Officer By Investing.com - Investing.com Nigeria

Jun 25, 2025

Jun 25, 2025

Vistagen (VTGN) Appoints Elissa Cote as Chief Corporate Development Officer | VTGN Stock News - GuruFocus

Jun 25, 2025

Jun 25, 2025

Vistagen appoints Elissa Cote as Chief Corporate Development Officer - Investing.com

Jun 25, 2025

Jun 23, 2025

William Blair Issues Negative Forecast for VTGN Earnings - Defense World

Jun 23, 2025

Jun 22, 2025

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript - Insider Monkey

Jun 22, 2025

Jun 21, 2025

William Blair Reiterates Outperform Rating for VistaGen Therapeutics (NASDAQ:VTGN) - MarketBeat

Jun 21, 2025

Jun 20, 2025

Vistagen Therapeutics (VTGN): Can Fasedienol's Phase 3 Success Overcome Financial Strains? - AInvest

Jun 20, 2025

Jun 19, 2025

Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

Jun 19, 2025

Jun 19, 2025

VistaGen Therapeutics (NASDAQ:VTGN) Receives Outperform Rating from William Blair - Defense World

Jun 19, 2025

Jun 18, 2025

Stifel reiterates buy rating on VistaGen stock amid clinical progress By Investing.com - Investing.com Canada

Jun 18, 2025

Jun 18, 2025

Vistagen (VTGN) Advances Fasedienol for Social Anxiety Treatment - GuruFocus

Jun 18, 2025

Jun 18, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo News Canada

Jun 18, 2025

Jun 18, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses - GuruFocus

Jun 18, 2025

Jun 17, 2025

Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks

Jun 17, 2025

Jun 17, 2025

Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline - MSN

Jun 17, 2025

Jun 17, 2025

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - sharewise

Jun 17, 2025

Jun 17, 2025

Earnings call transcript: Vistagen’s focus on innovation amid rising expenses Q1 2025 - Investing.com India

Jun 17, 2025